We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1Asst. Prof. Rajesh Bhaiyya Tope College of Pharmacy, Chhatrapati Sambhaji Nagar, Maharashtra India
2Asst. Prof. Rajshree College of Pharmacy, Mehkar, Maharashtra India
3M. Pharm, Department of Pharmaceutical Quality Assurance, H. R. Patel Institute of Pharmaceutical Education and Research Shirpur, Maharashtra India.
4B. Pharmacy, Shri Sant Gajanan Maharaj College of Pharmacy, Buldhana, Maharashtra India
5Rajarshi Shahu College of Pharmacy, Buldhana, Maharashtra India
Pharmacognosy plays a pivotal role in identifying, extracting, and standardizing bioactive phytocompounds that form the basis of numerous modern and traditional medicines. However, challenges such as overharvesting, habitat loss, climate change, and long growth cycles hinder sustainable production of medicinal plants. 3D bioprinting, an advanced additive manufacturing technology, offers a novel approach to plant tissue engineering by enabling precise spatial organization of plant cells within custom bioinks for scalable, controlled phytochemical synthesis. This review explores the intersection of 3D bioprinting and pharmacognosy, highlighting its potential in conservation of endangered medicinal plants, optimization of secondary metabolite production, and development of customized phytomedicine delivery systems. We discuss key bioprinting modalities inkjet, extrusion-based, and laser-assisted and their adaptation for plant cells, along with bioink formulations tailored for viability, differentiation, and metabolite yield. Case studies demonstrate successful production of high-value compounds such as paclitaxel, vincristine, and artemisinin from bioprinted plant constructs. Advantages over conventional plant tissue culture include improved reproducibility, scalability, and reduced environmental dependence. The review also addresses challenges in bioink optimization, large-scale manufacturing, cost, and regulatory frameworks. Future prospects encompass AI-guided construct design, portable on-demand phytochemical production in remote or space environments, and integration with synthetic biology for programmable metabolite pathways. By converging biotechnology, additive manufacturing, and traditional pharmacognosy, 3D bioprinting holds promise as a transformative tool for sustainable drug development and biodiversity preservation.
Pharmacognosy, the scientific discipline concerned with the study of medicinal plants, fungi, and other natural sources, has historically been a cornerstone of drug discovery. It encompasses the identification, extraction, characterization, and quality control of bioactive natural products that form the basis of both traditional and modern therapeutics (1). Over 50% of clinically approved drugs are derived from, or inspired by, natural compounds, highlighting pharmacognosy’s central role in the pharmaceutical pipeline (2). In the modern research era, pharmacognosy integrates advanced techniques such as metabolomics, molecular docking, and biotechnology to optimize the discovery and utilization of bioactive molecules (3). Bioactive phytocompounds secondary metabolites such as alkaloids, flavonoids, terpenoids, saponins, and phenolic acids are crucial in both ethnomedicine and evidence-based pharmacotherapy. They exhibit diverse pharmacological activities including anti-inflammatory, antimicrobial, anticancer, and neuroprotective effects (4). In traditional medicine systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Unani, plant-derived phytochemicals are central to therapeutic practice. In modern medicine, compounds like paclitaxel, artemisinin, and vincristine illustrate how plant-derived molecules can be translated into globally significant drugs (5). The increasing demand for phytochemicals has introduced several critical challenges to the conservation and large-scale production of medicinal plants. Firstly, overharvesting and habitat loss (6) continue to threaten biodiversity and jeopardize the sustainability of natural populations. Secondly, climate change (7) has a significant impact on the biosynthesis of phytochemicals, often leading to variations in both the quality and yield of these compounds. Another major hurdle is the lengthy growth cycles of many medicinal plants (8), which limit their scalability for industrial production. In addition, batch-to-batch variability in the content of active compounds (9) creates difficulties in achieving consistent and standardized drug formulations. Although biotechnological approaches such as plant tissue culture and metabolic engineering (10) have been employed to address these problems, they still fall short in delivering large-scale, cost-effective production systems.3D bioprinting, originally developed for regenerative medicine, has emerged as a promising tool for producing complex biological constructs with high spatial precision. In pharmacognosy, it offers the possibility of creating plant cell-based bio-inks, enabling on demand production of phytochemicals under controlled conditions without relying on seasonal growth cycles (11). Techniques such as extrusion-based printing, inkjet bioprinting, and laser-assisted bioprinting can be adapted to print viable plant tissues capable of sustained metabolite biosynthesis (12). Additionally, 3D printing facilitates the design of customizable dosage forms incorporating plant extracts, thereby improving drug delivery, stability, and patient compliance (13). This review aims to explore the convergence of 3D bioprinting technologies and pharmacognosy as a sustainable, scalable, and innovative approach to the conservation and production of bioactive phytocompounds. We assess current advancements in plant cell-based bio-inks, explore bioprinted phytochemical production systems, and discuss their potential in reducing dependence on wild plant harvesting. Furthermore, the review outlines challenges in bio-ink formulation, scaling, and regulatory approval, and presents future research trajectories towards integrating 3D bioprinting into herbal drug development pipelines.
Priyanka Nemane*, Pooja Sable, Sudam Veer, Samadhan More, Shivhari Doifode, Tejas Gorle, Vivek Dengale, Parimal Mendhe, Om Magar, Aditya Pawar, Mohini Kale, Ashwini Verulkar, Shivshankar Nagrik, 3D Bioprinting In Pharmacognosy: A Future Tool for Conservation and Production of Bioactive Phytocompounds, Int. J. Sci. R. Tech., 2025, 2 (8), 202-217. https://doi.org/10.5281/zenodo.16836111
10.5281/zenodo.16836111